{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:06:07Z","timestamp":1792857967878,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["No.2023YFC2308500"],"award-info":[{"award-number":["No.2023YFC2308500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["No.2021YFF1201304"],"award-info":[{"award-number":["No.2021YFF1201304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No.82373301"],"award-info":[{"award-number":["No.82373301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No.82172751"],"award-info":[{"award-number":["No.82172751"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No.82400664"],"award-info":[{"award-number":["No.82400664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No.82404077"],"award-info":[{"award-number":["No.82404077"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangzhou Science and Technology Project","award":["No.202201011183"],"award-info":[{"award-number":["No.202201011183"]}]},{"name":"the Postdoctoral Fellowship Program of CPSF","award":["No.GZC20240663"],"award-info":[{"award-number":["No.GZC20240663"]}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Natural Science Foundation","doi-asserted-by":"crossref","award":["No.2022A1515110656"],"award-info":[{"award-number":["No.2022A1515110656"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Although metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with high multimorbidity and mortality, existing classification systems and risk prediction models largely ignore the heterogeneity of MASLD. Improved subtype definition could improve prediction of outcomes and inform new precision treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed individuals with MASLD from population-based electronic health record resource from UK Biobank (n\u2009=\u2009125,197) and Health examinee dataset of Nanfang Hospital (n\u2009=\u2009995). We identified subtypes with K-means clustering method. The Cox proportional hazard regression model analyzed the relationship between variables and MASLD-related complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After identifying five clusters across seven clinical indicators which were age, body mass index, monocyte\/lymphocyte ratio, aspartate aminotransferase, waist-hip ratio, low-density lipoprotein-cholesterol, and cholesterol, we labelled MASLD subtypes: (1) Metabolic-Dyslipidemia, (2) Younger, (3) Obesity, (4) Inflammatory, and (5) Hepatotoxic. Metabolic outcomes differed across these five subtypes. Hepatotoxic MASLD showed an increased risk of severe liver diseases compared to Metabolic-Dyslipidemia MASLD [HR\u2009=\u200913.9, 95% CI 10.7\u201318.1]. The extrahepatic complications were highest in Inflammatory MASLD. These two groups were defined as the high-risk group with higher health burden than other three groups, which classified as low-risk group. Differential single-nucleotide polymorphisms were concentrated on chromosomes 1 and 19 when comparing the high- and low-risk groups, and the annotated genes enrichment pathways were primarily related to lipid metabolism and transport.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patient subtypes derived by clinical indicators are a valuable addition to existing MASLD classification systems, which could provide a valuable tool to aid in selecting specific treatment approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-06670-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T11:43:04Z","timestamp":1752147784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine"],"prefix":"10.1186","volume":"23","author":[{"given":"Chang","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-xing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-zhe","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-ren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5265-4159","authenticated-orcid":false,"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-shan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"6670_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"Hepatology"},{"key":"6670_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.02.001","author":"CD Byrne","year":"2025","unstructured":"Byrne CD, Dore GJ. Metabolic dysfunction-associated steatotic liver disease a multisystem disease: assessing the cost effectiveness of pharmacotherapies. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.001.","journal-title":"J Hepatol"},{"issue":"1","key":"6670_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8(1): e2454707.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"6670_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/apt.17631","volume":"58","author":"VL Chen","year":"2023","unstructured":"Chen VL, Song MW, Suresh D, et al. Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease. Aliment Pharmacol Ther. 2023;58(5):537\u201345.","journal-title":"Aliment Pharmacol Ther"},{"key":"6670_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2025.112518","volume":"601","author":"C Brummer","year":"2025","unstructured":"Brummer C, Singer K, Renner K, et al. The spleen-liver axis supports obesity-induced systemic and fatty liver inflammation via MDSC and NKT cell enrichment. Mol Cell Endocrinol. 2025;601: 112518.","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"6670_CR6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","volume":"75","author":"GN Ioannou","year":"2021","unstructured":"Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476\u201384.","journal-title":"J Hepatol"},{"issue":"4","key":"6670_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6670_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433.","journal-title":"Metabolism"},{"issue":"12","key":"6670_CR9","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018\u201330.","journal-title":"Liver Int"},{"issue":"10","key":"6670_CR10","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138\u201347.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6670_CR11","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/j.jhep.2023.08.003","volume":"80","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and\/or MAFLD. J Hepatol. 2023;80:e62\u20134.","journal-title":"J Hepatol"},{"issue":"1","key":"6670_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"key":"6670_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104489","volume":"89","author":"A Dashtban","year":"2023","unstructured":"Dashtban A, Mizani MA, Pasea L, et al. Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals. EBioMedicine. 2023;89: 104489.","journal-title":"EBioMedicine"},{"issue":"6","key":"6670_CR14","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2589-7500(23)00065-1","volume":"5","author":"A Banerjee","year":"2023","unstructured":"Banerjee A, Dashtban A, Chen S, et al. Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study. Lancet Digit Health. 2023;5(6):e370\u20139.","journal-title":"Lancet Digit Health"},{"issue":"6","key":"6670_CR15","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/jamia\/ocaa338","volume":"28","author":"B Chen","year":"2021","unstructured":"Chen B, Alrifai W, Gao C, et al. Mining tasks and task characteristics from electronic health record audit logs with unsupervised machine learning. J Am Med Inform Assoc. 2021;28(6):1168\u201377.","journal-title":"J Am Med Inform Assoc"},{"issue":"16","key":"6670_CR16","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198\u2013208.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6670_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7030","volume":"6","author":"EC Francis","year":"2023","unstructured":"Francis EC, Kechris K, Jansson T, et al. Novel metabolic subtypes in pregnant women and risk of early childhood obesity in offspring. JAMA Netw Open. 2023;6(4): e237030.","journal-title":"JAMA Netw Open"},{"key":"6670_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06184-7","author":"B Salvatori","year":"2024","unstructured":"Salvatori B, Wegener S, Kotzaeridi G, et al. Identification and validation of gestational diabetes subgroups by data-driven cluster analysis. Diabetologia. 2024. https:\/\/doi.org\/10.1007\/s00125-024-06184-7.","journal-title":"Diabetologia"},{"issue":"4","key":"6670_CR19","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","volume":"20","author":"Z Liu","year":"2022","unstructured":"Liu Z, Suo C, Shi O, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin Gastroenterol Hepatol. 2022;20(4):e855\u201375.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6670_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101153","volume":"48","author":"J Boeckmans","year":"2025","unstructured":"Boeckmans J, Prochaska JH, Gieswinkel A, et al. Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study. Lancet Reg Health Eur. 2025;48: 101153.","journal-title":"Lancet Reg Health Eur"},{"issue":"23","key":"6670_CR21","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.3390\/nu16234178","volume":"16","author":"M Antentas","year":"2024","unstructured":"Antentas M, Rojo-Lopez MI, Vendrell P, et al. Impact of dietary niacin on metabolic dysfunction-associated steatotic liver disease in mediterranean subjects: a population-based study. Nutrients. 2024;16(23):4178.","journal-title":"Nutrients"},{"issue":"10","key":"6670_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101172","volume":"6","author":"V Mannisto","year":"2024","unstructured":"Mannisto V, Salomaa V, Jula A, et al. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population. JHEP Rep. 2024;6(10): 101172.","journal-title":"JHEP Rep"},{"key":"6670_CR23","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023;80:e51\u20132.","journal-title":"J Hepatol"},{"key":"6670_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155666","volume":"147","author":"M Kouvari","year":"2023","unstructured":"Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, et al. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study. Metabolism. 2023;147: 155666.","journal-title":"Metabolism"},{"issue":"5","key":"6670_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","volume":"73","author":"H Hagstrom","year":"2020","unstructured":"Hagstrom H, Talback M, Andreasson A, et al. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73(5):1023\u20139.","journal-title":"J Hepatol"},{"issue":"10","key":"6670_CR26","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"6670_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41366-021-01015-w","volume":"46","author":"A De Vincentis","year":"2022","unstructured":"De Vincentis A, Tavaglione F, Spagnuolo R, et al. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes (Lond). 2022;46(3):486\u201393.","journal-title":"Int J Obes (Lond)"},{"issue":"11","key":"6670_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003830","volume":"18","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang H, Li S, et al. Consumption of coffee and tea and risk of developing stroke, dementia, and poststroke dementia: a cohort study in the UK Biobank. PLoS Med. 2021;18(11): e1003830.","journal-title":"PLoS Med"},{"issue":"16","key":"6670_CR29","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/eurheartj\/ehaa1031","volume":"42","author":"M Wang","year":"2021","unstructured":"Wang M, Zhou T, Song Y, et al. Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank. Eur Heart J. 2021;42(16):1582\u201391.","journal-title":"Eur Heart J"},{"issue":"3","key":"6670_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/jcsm.12705","volume":"12","author":"TJ Wilkinson","year":"2021","unstructured":"Wilkinson TJ, Miksza J, Yates T, et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. J Cachexia Sarcopenia Muscle. 2021;12(3):586\u201398.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7726","key":"6670_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203\u20139.","journal-title":"Nature"},{"issue":"11","key":"6670_CR32","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/s41588-021-00954-4","volume":"53","author":"L Jiang","year":"2021","unstructured":"Jiang L, Zheng Z, Fang H, et al. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021;53(11):1616\u201321.","journal-title":"Nat Genet"},{"issue":"12","key":"6670_CR33","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi O, De Vincentis A, Tavaglione F, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(12):3614\u201323.","journal-title":"Nat Med"},{"issue":"12","key":"6670_CR34","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(12):3624\u201333.","journal-title":"Nat Med"},{"key":"6670_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.035","author":"LA Diaz","year":"2025","unstructured":"Diaz LA, Alazawi W, Agrawal S, et al. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.035.","journal-title":"J Hepatol"},{"issue":"5","key":"6670_CR36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcsm.12754","volume":"12","author":"HS Chun","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2021;12(5):1168\u201378.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"6670_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13757","volume":"16","author":"TS Lim","year":"2025","unstructured":"Lim TS, Kwon S, Bae SA, et al. Association between handgrip strength and cardiovascular disease risk in MASLD: a prospective study from UK biobank. J Cachexia Sarcopenia Muscle. 2025;16(2): e13757.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6670_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155294","volume":"136","author":"J Ye","year":"2022","unstructured":"Ye J, Zhuang X, Li X, et al. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation. Metabolism. 2022;136: 155294.","journal-title":"Metabolism"},{"issue":"7","key":"6670_CR39","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/17474124.2021.1914587","volume":"15","author":"G Tarantino","year":"2021","unstructured":"Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2021;15(7):759\u201369.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6670_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118086","volume":"187","author":"M Matboli","year":"2025","unstructured":"Matboli M, Saad M, Ahmed MF, et al. Febuxostat alleviate metabolic dysfunction-associated steatohepatitis in rat model via targeting inflammation, cell death, and intestinal barrier dysfunction. Biomed Pharmacother. 2025;187: 118086.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"6670_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.tips.2025.03.008","volume":"46","author":"X Palomer","year":"2025","unstructured":"Palomer X, Wang J, Escalona C, et al. Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD. Trends Pharmacol Sci. 2025;46(6):551\u201366.","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"6670_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2502978122","volume":"122","author":"I Sakuma","year":"2025","unstructured":"Sakuma I, Gaspar RC, Nasiri AR, et al. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis. Proc Natl Acad Sci U S A. 2025;122(18): e2502978122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6670_CR43","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/ijms20061277","volume":"20","author":"V Basyte-Bacevice","year":"2019","unstructured":"Basyte-Bacevice V, Skieceviciene J, Valantiene I, et al. TM6SF2 and MBOAT7 gene variants in liver fibrosis and cirrhosis. Int J Mol Sci. 2019;20(6):1277.","journal-title":"Int J Mol Sci"},{"key":"6670_CR44","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","volume":"5","author":"Y Liu","year":"2014","unstructured":"Liu Y, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.","journal-title":"Nat Commun"},{"key":"6670_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101146","volume":"50","author":"DY Vos","year":"2021","unstructured":"Vos DY, van de Sluis B. Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). Mol Metab. 2021;50: 101146.","journal-title":"Mol Metab"},{"issue":"11","key":"6670_CR46","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI29383","volume":"116","author":"TA Lagace","year":"2006","unstructured":"Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116(11):2995\u20133005.","journal-title":"J Clin Invest"},{"issue":"20","key":"6670_CR47","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855\u201364.","journal-title":"N Engl J Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06670-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06670-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06670-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:35:31Z","timestamp":1757223331000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06670-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6670"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06670-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The UK Biobank received ethics approval from the Northwest Multicenter Research Ethics Committee (11\/NW\/0382). The health examinee dataset of Nanfang Hospital is granted by the Medical Ethics Committee of Nanfang Hospital, Southern Medical University (NFEC-2019-161). All research was conducted in accordance with both the Declarations of Helsinki and Istanbul. Appropriate informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors confirm that this manuscript does not contain any personal data or images from any individual participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"769"}}